Health Care

Sanofi's net profit slipped 2.4 percent in the third quarter as the maker of the Lantus diabetes treatment booked a higher charge for restructuring at its French operations.

Shares of medical equipment maker Becton, Dickinson and Co. and rival CareFusion both bounced above their 52-week highs Monday before markets opened and a day after the companies announced their $12.2 billion combination.

Shares of companies that are studying potential vaccines for Ebola climbed after federal officials announced that the first case of the disease has been diagnosed in the U.S.

Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.

Shares of Intercept Pharmaceuticals Inc. soared in premarket trading Tuesday, a day after the drug developer said its most advanced candidate performed better than a placebo in a mid-stage study of patients with a form of chronic liver disease.

When swings in the stock market cause anxiety to spike, like it is now, many investors aim to get healthy.

A year after Americans recoiled at new revelations that sick veterans were getting sicker while languishing on waiting lists — and months after the Department of Veterans Affairs instituted major reforms costing billions of dollars — government data shows that the number of patients facing long waits at VA facilities has not dropped at all.

The hospital where a man diagnosed with Ebola died and two nurses were infected with the virus says its revenue and patient roles have plummeted.

As a group, biotech companies were among the best performers in what was a stellar year for US stocks: The group was up 66%, outpacing the broader market by a staggering 3600 basis points.  

Few places illustrate the growing gap separating the rich from everyone else as starkly as the Hamptons, the summer playground for the have and have-mores.

Vanguard founder Jack Bogle told FBN’s Maria Bartiromo that Wal-Mart’s decision to cut health insurance benefits for some part-time workers could have long-lasting negative effects on the company.

Making the case for more M&A in 2016.

Fraud allegations rock Valeant Pharmaceuticals.

Opko Health's finance head, Juan Rodriguez, will step down to pursue other business interests but will continue to provide services in a consulting capacity.

NIH’s top doctor talks Ebola, health, and what keeps him up at night.

Transforming grief into drive to transform the medical world. MedImmune head Bahija Jallal leads the push to bring a new kind of science to biotech heavyweight AstraZeneca.

Valeant Pharmaceuticals agreed on Monday to buy Medicis Pharmaceutical for $44 per share, a 39% premium to Medicis stock's closing price of $31.56 on Friday.

Regulators extended its review of Pfizer's experimental rheumatoid arthritis treatment tofacitinib, one of the most promising new drugs in the company's pipeline.

The $8.50-a-share deal represents a 27% premium on the cancer treatment maker's Tuesday closing price.